Search alternatives:
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
nm decrease » _ decrease (Expand Search), we decrease (Expand Search), gy decreased (Expand Search)
nn decrease » _ decrease (Expand Search), gy decreased (Expand Search), b1 decreased (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
5 nm » 5 mm (Expand Search), 5 cm (Expand Search)
-
361
Addressing a Trapped High-Energy Water: Design and Synthesis of Highly Potent Pyrimidoindole-Based Glycogen Synthase Kinase-3β Inhibitors
Published 2021“…Surprisingly, our results demonstrate that this high-energy water was not displaced by our potent inhibitor (<i>S</i>)-3-(3-((7-ethynyl-9<i>H</i>-pyrimido[4,5-<i>b</i>]indol-4-yl)(methyl)amino)piperidin-1-yl)propanenitrile (<b>(<i>S</i>)</b>-<b>15</b>, IC<sub>50</sub> value of 6 nM). …”
-
362
-
363
Longer <i>L</i><sub><i>h</i></sub> significantly decreases and delays the peak of the sound-evoked CAPs of SGN fibers.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations of varying heminode length <i>L</i><sub><i>h</i></sub> at 70dB SPL, averaged over 50 simulations. …”
-
364
Longer <i>L</i><sub><i>u</i></sub> significantly decreases and delays the peak of the sound-evoked CAPs of SGN fibers.
Published 2021“…<p>(A) Sound-evoked CAPs of SGN fiber populations with varying unmyelinated segment length <i>L</i><sub><i>u</i></sub> at 70dB SPL, averaged over 50 simulations. …”
-
365
-
366
DataSheet_1_Decreased TCF1 and BCL11B expression predicts poor prognosis for patients with chronic lymphocytic leukemia.docx
Published 2022“…<p>T cell immune dysfunction is a prominent characteristic of chronic lymphocytic leukemia (CLL) and the main cause of failure for immunotherapy and multi-drug resistance. …”
-
367
-
368
-
369
-
370
-
371
-
372
-
373
-
374
-
375
-
376
-
377
-
378
-
379
-
380